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StatinEven though oxidative stress damage from excessive production of ROS is awell knownphenomenon, the impact
of reductive stress remains poorly understood. This study tested the hypothesis that cellular reductive stress
could lead to mitochondrial malfunction, triggering a mitochondrial hormesis (mitohormesis) phenomenon
able to protect mitochondria from the deleterious effects of statins. We performed several in vitro experiments
on L6 myoblasts and studied the effects of N-acetylcysteine (NAC) at different exposure times. Direct NAC expo-
sure (1mM) led to reductive stress, impairingmitochondrial function by decreasingmaximal mitochondrial res-
piration and increasing H2O2 production. After 24 h of incubation, the reactive oxygen species (ROS) production
was increased. The resulting mitochondrial oxidation activatedmitochondrial biogenesis pathways at the mRNA
level. After oneweek of exposure,mitochondria werewell-adapted as shown by the decrease of cellular ROS, the
increase ofmitochondrial content, aswell as of the antioxidant capacities. Atorvastatin (ATO) exposure (100 μM)
for 24 h increased ROS levels, reduced the percentage of live cells, and increased the total percentage of apoptotic
cells. NAC exposure during 3 days failed to protect cells from the deleterious effects of statins. On the other hand,
NAC pretreatment during one week triggered mitochondrial hormesis and reduced the deleterious effect of
statins. These results contribute to a better understanding of the redox-dependant pathways linked tomitochon-
dria, showing that reductive stress could trigger mitochondrial hormesis phenomenon.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The mitochondrion is the most important organelle in determining
continued cell survival and cell death. In most cell types, mitochondria
are the major source of reactive oxygen species (ROS), which affect ap-
optosis both directly and indirectly via the activation of transcription
factors [1]. For a long time, ROS were considered exclusively unwanted
by-products of oxidative phosphorylation, as high concentrations of
ROS cause lipid peroxidation and damage to cell membranes, proteins,
carbohydrates, and DNA [2]. In the last decade, it has been shown that
low, non-cytotoxic concentrations of ROS can serve as signals, triggering
the activation of speciﬁc pathways [3–10]. The preservation of this non-
cytotoxic level of ROS is ensured by antioxidant systems, which play
a major role in cellular redox homeostasis. A deﬁciency or defect in
these systems leads to an increase in tissue damage. In such cases,
ROS can act either as secondmessengers or as a source of cellular dam-
age, depending on the level of ROS production [4,6,7,11]. The concept ofculté de Médecine, EA 3072, 11
34 36; fax: +33 3 68 85 34 44.mitochondrial hormesis, or “mitohormesis”, proposes that low doses of
mitochondrial ROS can activate mitochondrial biogenesis and antioxi-
dant capacities in order to counteract oxidative stress and to re-
establish homeostasis [4,5,7,8,12].
The development of chronic oxidative stress has been implicated in
the metabolic myopathy that is a secondary symptom of numerous pa-
thologies such as diabetes mellitus, heart failure, or chronic obstructive
pulmonary disease (COPD) [13,14]. This myopathy is also the most
common adverse event encountered in patients treated with statins
(HMG-CoA inhibitors, used to lower the plasmatic cholesterol levels),
the most frequently prescribed treatment in developed countries.
Recently, we found that statins protect mitochondria in the highly
oxidative cardiac muscle by triggering a mitohormesis mechanism but
impair mitochondrial function in glycolytic skeletal muscle [4].
Therefore, strategies involving moderate mitochondrial stress, in-
ducing a mitohormesis mechanism may be used for the development
of new ROS-targeting drugs. This would result in reducing the symp-
toms of metabolic myopathies by strengthening muscular mitochon-
drial function [11,15].
Even though oxidative stress damage from excessive production
of ROS is a well known phenomenon, the impact of reductive stress
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of reducing equivalents (NAD(P)H and/or GSH) in the presence of intact
oxido-reductive systems [2]. N-acetylcysteine (NAC) is the acetylated
form (efﬁciently metabolized) of cysteine and is the most immediate
precursor of glutathione (GSH). TheGSH system is themainmechanism
of detoxiﬁcation of free radicals and ionized metabolites [16,17], and
it is partly localized in the mitochondria. NAC is mainly used for its
mucolytic action on the disulﬁde bonds of mucoproteins [18] and its
modulating action on oxidative stress [19]. Interestingly, it has been
shown that NAC treatment in H9C2 cells led to reductive stress [20].
This condition paradoxically increased the level ofmitochondrial oxida-
tion. However, the consequences as well as the potential beneﬁcial ef-
fects following this reductive stress-inducing mitochondrial oxidation
remained undiscovered [2].
We hypothesized that NAC treatment could change the redox envi-
ronment of the cell, inducing mitochondrial oxidation (as described by
[2,20]) and triggering a mitohormesis phenomenon, protecting L6 myo-
blasts from the deleterious effects of statins.
Therefore, we investigated the effects of N-acetylcysteine on L6myo-
blasts. We found that NAC induced cellular reductive stress, which had
for consequence an inhibitory effect on the mitochondrial respiratory
chain, leading to an increase inmitochondrial ROS production andmito-
chondrial oxidation. This triggered mitochondrial biogenesis pathways
and led to an increase in the number ofmitochondria and in antioxidant
capacities after 7 days of incubation. Finally, we showed that mitochon-
drial hormesis, triggered by NAC, protected cells against statin-induced
apoptosis.
2. Materials and methods
2.1. Cell culture
L6 ratmyoblastswere grown in Dulbecco'smodiﬁed Eagle'smedium
(DMEMLowglucose,Milerium,VWR International) supplementedwith
20% fetal calf serum (FCS) and 1% antibiotics (100 U/ml penicillin and
100 μg/ml streptomycin; Gibco) at 37 °C under a humidiﬁed 5% CO2 at-
mosphere. These cells were obtained from the American Type Culture
Collection (ATCC, Rockville, MD).
The acute effects of N-acetylcysteine (Sigma)were studied at several
doses (50 μM, 500 μM, 1 mM, and 5 mM) for mitochondrial respiration,
H2O2 production, and for the detection of superoxide production by
electron spin resonance (ESR).
The chronic effects of N-acetylcysteine on L6myoblastswere studied
by incubation with 1 mM of NAC in the culture medium for 24 h, three
days, and one week. For the three days and one-week experiments,
cells were also incubated with 100 μM atorvastatin for the last 24 h, in
DMEM containing 10% FCS and 1% antibiotics.
2.2. Cell viability assays
Cell viability assays were performed after 24 h or one week of incu-
bation with or without 1 mM NAC in DMEM containing 20% FCS, using
a Muse™ Cell Analyzer (Merck Millipore), with the Muse Count and
Viability Assay kit (Merck Millipore, Cat. Number: MCH100102), fol-
lowing the manufacturer's indications.
2.3. Study of mitochondrial respiration by oximetry
Mitochondrial respiration was studied in saponin-skinned cells to
keep mitochondria in their architectural environment [4]. The analysis
took place in a thermostated oxygraphic chamber at 37 °C with contin-
uous stirring (Oxygraph-2 k, Oroboros instruments, Innsbruck, Austria).
Cells were collected with trypsin and placed in R+ medium (2.77 mM
CaK2EGTA, 7.23 mM K2EGTA, 6.56 mM MgCl2, 20 mM imidazole,
20 mM taurine, 0.5 mM dithiothreitol, 50 mM K-methane sulfonate,
5 mM glutamate, 2 mM malate, 3 mM phosphate, and 2 mg/ml ofBSA; pH = 7) in the oxygraphic chamber with saponin (0.125 mg/ml
per chamber). Maximal respiration rate (Vmax) was measured in
the presence of saturating amounts of succinate (25 mM) and ADP
(2 mM) as substrates. Vmax characterizes the electron ﬂow through
complexes I, II, III, and IV. NAC was directly injected into the oxygraphic
chamber after Vmax. After the experiments, cells were collected for total
protein content determination. Results are expressed as a percentage of
the Vmax or of the control group.
2.4. H2O2 production in permeabilized cells
H2O2 production was measured with the Amplex Red reagent
(Invitrogen), which reacted with H2O2 in a 1:1 stoichiometry catalyzed
by HRP (Horse Radish Peroxidase; Fluka Biochemika) to yield the ﬂuo-
rescent compound resoruﬁn and molar equivalent O2 [21]. Resoruﬁn
has excitation/emission characteristics of 563/587 nm and is extremely
stable once formed. Fluorescence was measured continuously [change
in ﬂuorescence (F)/s] with a Fluoromax-4 (Jobin Yvon) spectroﬂuorom-
eterwith temperature control (set at 37 °C) and under continuousmag-
netic stirring.
Approximately 300,000 cells were added to 600 μl of buffer Z
(110 mM K-MES, 35 mM KCl, 1 mM EGTA, 5 mM K2HPO4, 3 mM
MgCl2, and 0.5 mg/ml BSA) with HRP (0.5 U/ml) and Amplex Red
(5 μM). Saponin was directly added to allow cell permeabilization
(0.125 mg/ml saponin). H2O2 production was then measured with glu-
tamate (5 mmol/l), malate (2 mmol/l), succinate (25 mM), and ADP
(2 mM) to stimulate electron ﬂow through complexes I, II, III, and IV.
To study the acute effects of NAC, 1 mM of NAC was then added in the
spectroﬂuorometer's quartz cell. H2O2 production rate was calculated
from the slope of F/s, after subtracting background, from a standard
curve established with the appropriate reaction conditions. At the con-
clusion of each experiment, cells were collected for total protein content
determination. Values are expressed as percentage of the control group.
2.5. Mitochondrial free radical leak (FRL)
H2O2 production and O2 consumption were measured in parallel in
the same sample under similar experimental conditions. This allowed
the calculation of the fraction of electrons out of sequencewhich reduce
O2 to ROS in the respiratory chain (the percentage of free radical leak)
instead of reaching cytochrome oxidase to reduce O2 to water [21].
Because two electrons are needed to reduce 1 mol of O2 to H2O2,
whereas four electrons are transferred in the reduction of 1 mol of
O2 to water, the percent of FRL was calculated as the rate of H2O2 pro-
duction divided by twice the rate of O2 consumption, and the result
was multiplied by 100.
2.6. NAD+/NADH determination
NAD+/NADH ratio was determined after 1H incubation with NAC
1mM, using the EnzyChrom™NAD+/NADHassay kit (BioAssay Systems,
Cat. Number: E2ND-100), following the manufacturer's instructions.
2.7. Electron spin resonance measurement of superoxide production
Superoxide (O2●−) productionwas determined after incubationwith
1 mM NAC for either 24 h, three days, or one week. For the three days
and one-week experiments, cells were also incubated with 100 μM
atorvastatin for the last 24 h, in DMEM containing 10% FCS and 1% anti-
biotics. Cells were placed into a 24-well plate with Krebs–Hepes Buffer
containing 25 μmol/l deferoxamine and 5 μmol/l DETC. Cells were
then incubated at 37 °C with the spin probe CMH (1-hydroxy-3-
methoxycarbonyl-2, 2, 5, 5-tetramethylpyrrolidine HCl, 200 μM) for
30 min under 2.7% oxygen, and 20 mm Hg partial pressure using a
Gas-Controller (Noxygen Sciences Transfer, Elzach, Germany). The reac-
tion was then stopped on ice. All ESR experiments measuring the
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e-scan M (Bruker biospin) in disposable capillary tubes, as previously
described [22]. Detection of superoxide was conducted under the
following ESR settings: center ﬁeld g = 3482.579; sweep width 60 G;
microwave power 21.85 mW; modulation amplitude 2.40 G; sweep
time 5.24 s; number of lag curve points 1.
2.8. Quantitative real time polymerase chain reaction (qRT-PCR)
Total RNA was obtained from cells using TRIzol™ (Invitrogen Life
Technologies, Rockville, MD, USA), as previously described [23] and
following the manufacturer's instructions. RNA was stored at−80 °C
until the reverse transcription reaction was performed. cDNA was
synthetized from total RNA with the SuperScript First-Strand Synthesis
System (Invitrogen) and random hexamer primers. To perform the
real-time PCR reaction, 1 μg of cDNA was mixed with 10 μM of each
primer (sense and antisense), SYBR Green (Invitrogen Life Technolo-
gies, Rockville, MD, USA) as a ﬂuorescent dye and H2O. The real-time
PCR measurement of individual cDNAs was performed in triplicate
using SYBR Green dye to measure duplex DNA formation with the
LightCycler System (Roche Diagnostics, Meylan, France). The primer se-
quences were designed using information contained in the public data-
base GenBank of the National Center for Biotechnology Information
(NCBI). The sequences of the primer sets used are listed in Table 1.
Quantiﬁcation of gene expression was performed by the method de-
scribed in [24], using the β-actin gene as the internal control because
it is a stable gene for real-time RT-PCR measurements in muscles. The
ampliﬁcation efﬁciency of each sample was calculated as described by
Ramakers et al. [25].
2.9. ATP monitoring assay
The intracellular concentration of ATP in myoblasts was measured
with the ATPLite 1-step kit from PerkinElmer Life and Analytical Sci-
ences (Shelton, CT, USA). Luminescence was detected with a Victor3Table 1
Primer sequences used for quantitative real-time PCR ampliﬁcation.
Target gene Organism Forward primer 5′→ 3′
Reverse primer 5′→ 3′
Accession number
PGC-1α Rat CACCAAACCCACAGAGAACAG
GCAGTTCCAGAGAGTTCCACA
NM_031347
PGC-1β Rat CCCCAGTGTCTGAAGTGGAT
TCTGGAACTGAGGCTGGTCT
NM_176075
NRF1 Rat GGCCCTTAACAGTGAAGCTG
CATCTGGGCCATTAGCATCT
NM_001100708
NRF2a Rat TACAATTGACCAGCCTGTGC
ATCCTTGGGGACCTTTGAAC
NP_001102311
NRF2b Rat CCCGATGGACAGCAAGTATT
CCGGTTCTCAATTATTTCCA
XM_006254075
TFAm Rat GAAAGCACAAATCAAGAGGA
CTGCTTTTCATCATGAGACAG
NM_031326
Catalase Rat AGATGGCACACTTTGACAGAGAG
GAGAATCGGACGGCAATAGGAG
NM_012520
SOD1 Rat AGATGACTTGGGCAAAGGTG
CAATCCCAATCACACCACAA
NM_017050
SOD2 Rat CTGGACAAACCTGAGCCCTA
GAACCTTGGACTCCCACAGA
NM_017051
Citrate
synthase
Rat TATGGCATGACGGAGATGAA
CATGGACTTGGGCCTTTCTA
DQ403126
Cox1 Rat CCAGAGTCATGAGTCGAAGGA
AGGCGCATGAGTACTTCTCGG
YP_665631
Cox4i1 Rat GTTGGCTACCAGGGCACTTA
CACATCAGGCAAGGGGTAGT
NP_058898
GPx Rat GCCGAGTGTGGTTTACGAAT
GGCTGCAAACTCCTTGATTT
NM_030826
Cytb Rat GCAGCTTAACATTCCGCCCAATCA
TACTGGTTGGCCTCCGATTCATGT
J01436
Pyruvate
kinase
Rat TGTGGGTGATCTGGTGATTGTGGT
AGGCATTTCAGGATACGCTCAGCA
NM_012624Wallac 1420 multilabel counter (PerkinElmer). ATP concentrations
were quantiﬁed according to a standard curve and expressed as per-
centage of the control group.2.10. mtDNA content
DNA was isolated from L6 myoblasts that had been treated with
1 mM NAC for one week. Brieﬂy, cells were placed in KTT lysis buffer
and vortexed. After centrifugation, phenol/chloroform premixed with
isoamyl alcohol (25:24:1; pH = 8; Interchim Uptima) was added to
the supernatant, followed by a centrifugation. Then chloroform was
added to the supernatant before another centrifugation. The aqueous
supernatantwas collected; ammonium acetate (4M, pH=7) and abso-
lute ethanol were added. Samples were precipitated for 1 h at−20 °C.
After centrifugation, pellets of DNA were washed two times with 70%
ethanol. Each pellet was dried and resuspended in 10 μl Tris–EDTA
buffer (TE). DNA in samples was quantiﬁed spectrophotometrically
at 260 nm. The DNA was subjected to real-time PCR in duplicate
(100 ng/μl). Relative amounts of nuclear and mtDNA were determined
by comparison of the ampliﬁcation kinetics of pyruvate kinase and cyto-
chrome b (Primer sequences in Table 1). Results were expressed as per-
centage of the control group.2.11. Measurement of total glutathione
Total glutathionewasmeasured in cells after oneweek of incubation
with NAC 1 mM according to the Akerboom and Sies method [26]
by monitoring the reduction of 5,5′-dithio-bis-2-nitrobenzoic acid
(DTNB) to 5-thio-2-nitrobenzoate (TNB) by GSH at 412 nm. Results
were expressed as μM/mg protein.2.12. Expression of PGC-1α, and SOD2
After one week incubation with NAC 1 mM, cells were lysed on ice
for 15 min with 200 μl of NET lysis buffer (0.05 M Tris–HCl pH 8.0,
50 mM NaCl, 5 mM EDTA, 1% NP-40 and a protease inhibitor tablet
from Roche, Basel, Switzerland). After lysis, the mixture was vortexed
and centrifuged for 10 min at 4 °C at 10,000 rpm. The supernatant was
collected and the protein concentration determined using the Pierce
BCA protein assay kit (Darmstadt, Germany). For each sample, 20 μg
of protein was separated on a denaturing SDS polyacrylamide gel
(4%). The antibodies against PGC-1α, and SOD2 were used at dilutions
of 1:1000, and 1:500, respectively (Goat polyclonal anti-PGC-1α anti-
body (ab106814) from Abcam PLC, Cambridge, UK; and Rabbit poly-
clonal anti-SOD2 antibody (ab13533) from Abcam PLC, Cambridge,
UK). Peroxidase-labeled anti-rabbit IgG or anti-goat IgG (1:2000 dilu-
tion) in combination with a chemiluminescent substrate (ECL Western
Blot detection kit, GE Healthcare, Amersham, UK) were used for the
analysis. Quantiﬁcation was performed using the ImageJ software
(National Institutes of Health). Results were expressed as percentage
of the control group.2.13. Apoptosis measurement assays
Apoptosismeasurement assayswere performed after three days and
oneweek of incubating L6 myoblasts with or without 1mMNAC and/or
100 μMatorvastatin for the ﬁnal 24 h, in DMEM containing 10% FCS and
1% antibiotics. Atorvastatin (Tahor) was generously provided by Pﬁzer.
Staurosporine (200 nM) was used as a positive control (data not
shown). The experimentswere performed using aMuse™ Cell Analyzer
(Merck Millipore), with the Muse Annexin V and dead cell kit (Merck
Millipore, Cat. Number: MCH100105), following the manufacturer's
instructions.
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Data are represented asmeans± SEM. Statistical analyses were per-
formed using Student's t test or 1-way ANOVA followed by a Tukey post
test (GraphPad Prism 5, Graph Pad Software, Inc., San Diego, CA, USA).
Statistical signiﬁcance was displayed as *, $p b 0.05 or **,$$p b 0.01
or ***, $$$p b 0.001.3. Results
3.1. Acute N-acetylcysteine exposure impaired mitochondrial function
The effects of NAC were ﬁrst observed at the cellular level: after 1 h
exposure of L6 cells with NAC 1 mM, NAD+/NADH ratio was decreased
compared to control (−72%; p b 0.05; Fig. 1A).
At the mitochondrial level, maximal mitochondrial respiration rates
(Vmax) and H2O2 production in saponin skinned cells were studied after
direct exposure. NAC decreased Vmax in a concentration-dependent
manner (Fig. 1B). The diminution of Vmax became signiﬁcant for a con-
centration of 0.5 mM (−19%; p b 0.05) and reached−28% at a concen-
tration of 1 mM (p b 0.01).
Fig. 1C showsmitochondrial H2O2 production frompermeabilized L6
cells. When cells were exposed to NAC 1 mM, there was an increase of
H2O2 production (+40%, p b 0.05) compared to control. The concentra-
tion of 1 mMwas used for further experiments because this concentra-
tion corresponded to a signiﬁcant decrease in Vmax combined with a
signiﬁcant increase of H2O2 production.
When L6 cells were directly exposed to NAC, the free radical leak
(FRL) was signiﬁcantly increased (+174%; p b 0.05; Fig. 1D) compared
to control.Fig. 1. Acute effects of NAC onmitochondrial function. (A) NAD+/NADH ratiomeasurement afte
drial maximal respiratory rates (Vmax) (n = 12). (C) Measurement of mitochondrial H2O2 pro
in the presence of NAC 1 mM, (n = 6). Values are expressed as means ± SEM, *p b 0.05; **p b
for (A, C and D).3.2. N-acetylcysteine increased mitochondrial ROS production and
triggered activation of mitochondrial biogenesis pathways after 24 h
L6 cells were treated with 1 mM NAC for 24 h. ESR measurements
showed an increase of superoxide production (+42%; p b 0.001)
(Fig. 2A). The cell viability assay did not show any difference between
CTL and NAC groups (Fig. 2B). Themaximal mitochondrial oxidative ca-
pacity of L6 cells was not altered (Fig. 2C) following 24 h of exposure. It
is important to underscore the fact that contrary to the acute time point,
we did not addNAC in the oxygraph chamber. The acceptor control ratio
(ACR) was not changed between the two groups (Fig. 2D).
The relativemRNA expression levels of themain actors inmitochon-
drial biogenesis, mitochondrial proteins, and of the main enzymatic an-
tioxidant systemsweremeasured by quantitative RT-PCR (Fig. 2E) after
this 24 h incubation with NAC. The relative expression level of PGC-1α
was decreased by 50% (p b 0.01), whereas the other actors of mitochon-
drial biogenesis were highly increased: PGC-1β (+240%; p b 0.001),
NRF1 (+174%; p b 0.001), and TFAm (+179%; p b 0.001) compared
to CTL. We observed signiﬁcant increases in the relative mRNA expres-
sion levels of COX1 (+372%; p b 0.001), COX4i1 (+281%; p b 0.01),
citrate synthase (+484%; p b 0.01), and SOD1 (+260%; p b 0.01) after
NAC exposure. In contrast, concerning the genes implicated in antioxi-
dant systems, there was no modiﬁcation of the relative mRNA expres-
sion levels of SOD2 or GPx.
3.3. One week of NAC incubation induced mitochondrial biogenesis
pathways, increasing mitochondrial content as well as antioxidant
enzymatic capacities, and reducing basal ROS production
After oneweek of incubation with 1mMNAC, the mRNA expression
levels of the main actors of mitochondrial biogenesis were increasedr 1 H incubation with NAC 1mM (n= 4). (B) Dose–response of NAC effects onmitochon-
duction in the presence of NAC 1 mM (n= 12). (D) Free radical leak (FRL) measurement
0.01; ***p b 0.001; One way ANOVA with repeated measures for (B) and unpaired t-test
Fig. 2. Chronic effects of NAC 1 mM (24 h). (A) Superoxide production was measured by ESR (CTL: n = 16; NAC: n = 23). (B) Cell viability assay realized with the MUSE Cell Analyzer
(n = 6). (C) Maximal mitochondrial oxidative capacities (Vmax) (n = 4). (D) Acceptor control ratio. (n = 4). (E) mRNA relative expression levels of factors involved in mitochondrial
biogenesis (PGC-1α, PGC-1β, NRF1, and TFAm), mitochondrial proteins (COX1, COX4i1, and citrate synthase), and antioxidant proteins (SOD1, SOD2, and GPx) were explored with or
without NAC (n = 11). Values are expressed as means ± SEM, **p b 0.01; ***p b 0.001; unpaired t-test.
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as NRF1 (+121%; p b 0.05), NRF2a (+62%; p b 0.05), NRF2b (+106%;
p b 0.01), and TFAm (+179%; p b 0.01). The relative mRNA expression
levels of several mitochondrial proteins were also upregulated, in-
cluding COX1 (+124%; p b 0.05), COX4i1 (+165%; p b 0.001), and
citrate synthase (+87%; p b 0.05). Concerning the antioxidant systems,
NAC exposure non-signiﬁcantly increased the level of catalase (+41%;
p = 0.08) and signiﬁcantly increased the relative mRNA expression
levels of SOD1 (+95%; p b 0.05), SOD2 (+107%; p b 0.01) and GPx
(+145%; p b 0.001).NAC treatment enhanced the protein expression of PGC-1α (+67%;
p b 0.05) conﬁrming the activation of the mitochondrial biogenesis
pathways (Fig. 3B). The increase in SOD2 protein expression with NAC
(+44%; p = 0.0683) conﬁrmed the augmentation of antioxidant ca-
pacities obtained at the mRNA level (Fig. 3B).
The increase inmitochondrial contentwas shownwith several tech-
niques (Western blotting, oxygraphy, quantiﬁcation of mitochondrial
DNA (mtDNA), and an ATP production assay).
Interestingly, the maximal mitochondrial oxidative capacity (Vmax,
+17%; p b 0.05) (Fig. 4A) as well as the mtDNA content were increased
Fig. 3. Chronic effects of NAC 1mM (1week) onmRNA expression as well as protein expression levels. (A)mRNA relative expression levels of factors involved inmitochondrial biogenesis
(PGC-1α, PGC-1β, NRF1, NRF2a, NRF2b, and TFAm), mitochondrial proteins (COX1, COX4i1, and citrate synthase), and antioxidant proteins (SOD1, SOD2, GPx, and catalase) (n = 5–6).
(B–C) Band intensity of Western blots of PGC-1α and of SOD2 (n = 6–7). Values are expressed as means ± SEM, *p b 0.05; **p b 0.01; ***p b 0.001; unpaired t-test.
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control ratio was not changed between the two groups (Fig. 4B). The
ATPmonitoring assay showed an important increase in the ATP content
after treatment with 1mMNAC (+303%; p b 0.001) (Fig. 4D). These re-
sults strongly suggest an activation of the cellularmetabolism after NAC
exposure, leading to the increase in mitochondrial content as well as
enzymatic antioxidant capacities.
We investigated the redox state of cells by studying the superoxide
production by ESR and the total cellular glutathione content. In cells
treated with NAC, it appeared that superoxide production was signiﬁ-
cantly diminished (−40%; p b 0.001; Fig. 4E) compared toCTL. Total cel-
lular glutathione content was increased after treatment (+38%;
p b 0.05; Fig. 4F) compared to CTL. No deleterious effects on cell viability
were observed after chronic NAC exposure (Fig. 4G).
3.4. Short NAC treatment (3 days) failed to protect cells from deleterious
effects of statins
Incubation ofmyoblastswith 100 μMatorvastatin for 24 h (ATO) im-
paired mitochondrial function (Fig. 5). Atorvastatin decreased themax-
imalmitochondrial oxidative capacity of cells (−37%; p b 0.001; Fig. 5A)
and the acceptor control ratio (−31%; p b 0.05; Fig. 5B). NAC pretreat-
ment for three days did not change either Vmax or ACR compared
to CTL. Short pretreatment with NAC did not protect maximal mito-
chondrial oxidative capacity of cells from the deleterious effect of ATO(NAC + ATO,−37%; p b 0.001; Fig. 5A), and did not improve the ACR
(−40%; p b 0.01; Fig. 5B) compared to CTL. Cellular ATP content
(Fig. 5C) decreased after 24 h of statin treatment (−29%; p b 0.05).
NAC pretreatment for three days did not change ATP content in cells.
ATP content in NAC + ATO group was reduced compared to CTL
(−61%; p b 0.001), aswell as to ATO (p b 0.05). Incubation ofmyoblasts
with ATO increased superoxide production (+37%; p b 0.05; Fig. 5D).
Superoxide production was not altered in NAC group compared to
CTL, whereas three days of pretreatment with NAC 1 mM did not
protect L6 cells from this high ROS production (NAC + ATO; +65%;
p b 0.001).
Apoptosis-measurement assays showed that atorvastatin incubation
for 24 h decreased cell viability (−21%; p b 0.001; Fig. 5E). Three days of
NAC pretreatment (NAC + ATO) did not prevent these deleterious ef-
fects of statins (−20%; p b 0.001 compared to CTL). NAC + ATO group
had a higher percentage of early apoptotic cells compared to the ATO
group (13.4% vs. 7%; p b 0.001; Fig. 5F). The percentage of late apoptotic
cells (Annexin V+/7-AAD+; Fig. 5G) was increased in both ATO and
NAC + ATO compared to CTL (20.41% and 14.78%, respectively;
p b 0.001). Moreover, the percentage of total apoptotic cells (early apo-
ptotic and late apoptotic; Fig. 5H) was increased in the ATO condition
compared to CTL (27.5% vs. 7%, respectively; p b 0.001) as well as in
the NAC+ATO condition (28.2%; p b 0.001 compared to CTL). NAC pre-
treatment alone did not change the percentage of total apoptotic cells
compared to CTL.
Fig. 4. Chronic effects of NAC 1 mM (1 week) on mitochondrial respiration, mitochondrial content and efﬁciency, oxidative stress and cell viability. (A) Maximal mitochondrial oxidative
capacities (Vmax) (n = 14–15). (B) Acceptor control ratio (n = 14–15). (C) mtDNA quantiﬁcation (n = 10–11). (D) ATP content determination assay (n = 12). (E) Superoxide pro-
duction measured by ESR (CTL: n = 14; NAC: n = 9). (F) Total glutathione content (n = 4). (G) Cell viability assay realized with the MUSE Cell Analyzer (n = 6). Values are expressed
as means ± SEM, *p b 0.05; ***p b 0.001; unpaired t-test.
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of statins
NAC pretreatment for one week, then 24 h with growth medium
containing 10% of FCS, increased maximal mitochondrial respiratory
rates (+22%; p b 0.05; Fig. 6A), without affecting the ACR (Fig. 6B),
and increased cellular ATP content (+59%; p b 0.001; Fig. 6C). Seven
days of pretreatment with NAC (NAC + ATO) prevented the alteration
of these parameters from the deleterious effects of ATO without im-
proving the ACR (+35% maximal respiratory rates compared to ATO,
p b 0.05; +29% ATP content compared to ATO, p b 0.001). Interestingly,
this NAC pretreatment protected L6 cells from this Atorvastatin-induced
ROS production (NAC + ATO,−26% compared to CTL, p b 0.05;−41%
compared to ATO, p b 0.001; Fig. 6D).
Apoptosis-measurement assays showed that atorvastatin incubation
for 24 h decreased cell viability (−10%; p b 0.001; Fig. 6E). The
NAC + ATO group had a higher percentage of viable cells compared tothe ATO group (83.2% vs. 78.4%, respectively; p b 0.001), although this
percentage remained lower than the control condition without atorva-
statin (−5%; p b 0.001). Atorvastatin incubation tend to increase
the percentage of cells in early apoptosis (Annexin V+/7-AAD−;
Fig. 6F) compared to the control group (13.8% vs. 10.4%, respectively;
p b 0.05). The NAC + ATO group had a lower percentage of early apo-
ptotic cells compared to the ATO group (10.4% vs. 13.8%; p b 0.05).
The percentage of late apoptotic cells (Annexin V+/7-AAD+; Fig. 6G)
was increased in both ATO and NAC + ATO compared to the control
(+323% and +276%, respectively; p b 0.001). The co-treatment did
not change the percentage of late apoptotic cells compared to the ATO
condition (6.4% vs. 7.2%, respectively). However, the percentage of
total apoptotic cells (early apoptotic and late apoptotic; Fig. 6H) was
increased in the ATO condition compared to CTL (21.5% vs. 13.5%,
respectively; p b 0.001) and NAC + ATO had a lower percentage of
total apoptotic cells compared to the ATO group (16.7% vs. 21.5%,
respectively; p b 0.05).
Fig. 5. NAC pretreatment for 3 days failed at protecting cells from deleterious effects of statins. (A) Maximal mitochondrial oxidative capacities (Vmax) (n = 7). (B) Acceptor control
ratio (n = 7). (C) ATP content determination assay (n = 6). (D) Superoxide productionmeasured by ESR (n=6). (E–H) Annexin V assay (n= 6): (E) Percentage of live cells (Annexin
V-PE−/7-AAD−). (F) Early apoptotic cells (Annexin V-PE+/7-AAD−). (G) Late apoptotic cells (Annexin V-PE+/7-AAD+). (H) Total apoptotic cells. Values are expressed as means ± SEM,
*p b 0.05; **p b 0.01; ***p b 0.001 compared to CTL; $p b 0.05; $$$p b 0.001 compared to ATO. One way ANOVA followed by a Tukey post test.
1581F. Singh et al. / Biochimica et Biophysica Acta 1853 (2015) 1574–15854. Discussion
This study showed that: (I) Acute treatment with N-acetylcysteine
induced a cellular reductive stress that impairedmitochondrial function
of myoblasts; (II) following this reductive stress, there was a rapid acti-
vation of mitochondrial biogenesis pathways (after 24 h of incubation);
(III) three days of NAC treatment was not sufﬁcient to induce a pheno-
typic adaptations allowing to protect cells from statins toxicity; (IV)
after one week of NAC exposure, the mitochondrial biogenesis pathways
remained activated, allowing an increase ofmitochondrial content aswellas antioxidant enzymatic capacities, corresponding to a mitohormesis
mechanism; (V) the activation of this mitohormesis phenomenon clearly
protected cells from apoptosis triggered by short statins treatment.
4.1. The antioxidant molecule N-acetylcysteine induced cellular reductive
stress, and mitochondrial oxidation by inhibiting the mitochondrial
respiratory chain
Our results showed that NAC treatment induced a cellular reductive
stress, as suggested by the reduction of the NAD+/NADH ratio. Our
Fig. 6. Protective effects of NAC-inducedmitohormesis phenomenon against deleterious effects of statins. (A) Maximal mitochondrial oxidative capacities (Vmax) (n= 6–8). (B) Acceptor
control ratio (n–6-8). (C) ATP content determination assay (n = 6). (D) Superoxide production measured by ESR (n = 6). (E–H) Annexin V assay (n = 6): (E) Percentage of live cells
(Annexin V-PE−/7-AAD−). (F) Early apoptotic cells (Annexin V-PE+/7-AAD−). (G) Late apoptotic cells (Annexin V-PE+/7-AAD+). (H) Total apoptotic cells. Values are expressed as
means ± SEM, *p b 0.05; **p b 0.01; ***p b 0.001 compared to CTL; $p b 0.05; $$$p b 0.001 compared to ATO. One way ANOVA followed by a Tukey post test.
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NAC could provoke glutathionylation of mitochondrial proteins due
to a NAC-induced reductive stress effect on H9C2 cardiomyocytes
[2,20,27]. Zhang et al. observed, that causing reductive stress with
NAC (4 mM) treatment for 60 min, induced an oxidation of the redox
state of mito-roGFP and that Trx 2 correspondingly shifted from 56%reduced form to 36% reduced form after NAC exposure compared with
controls [20].
Then, subunits of the respiratory chain complexes could be altered
by this mechanism, leading to oxidative phosphorylation (OXPHOS)
dysfunction and then to an increase in ROS production as shown by
the decrease of Vmax and increase of H2O2 production, leading to an
1583F. Singh et al. / Biochimica et Biophysica Acta 1853 (2015) 1574–1585increase of the free radical leak (FRL) [21,28,29]. The FRL represents the
fraction of electrons out of sequence that reduce O2 to ROS in the respi-
ratory chain (the percent of free radical leak) instead of reaching cyto-
chrome oxidase to reduce O2 to water [30]. The FRL is a good index of
mitochondrial oxidative stress [21] because it is independent of the mi-
tochondrial content, which is known to inﬂuence the production of ROS
[30]. Inhibition of mitochondrial respiration-induced mitochondrial
ROS production has already been shown in several other in vitromodels
[4,31–33], and both complex I and complex III should be potential sites
of O2●− production [29,34,35]. Then, in contrast to the general model in
which NAC functions solely as an antioxidant, we and others observed
that NAC could increase mitochondrial ROS production [2,20,36]. Our
ﬁndings underscore the importance of considering the dynamic events
related to oxido-reductive signals and redox-dependent pathways.
4.2. Reductive stress triggered a mitochondrial hormetic mechanism
Mitohormesis is based on the assumption that a moderate increase
in ROS production during mitochondrial activity leads to the activation
of cellular defense systems [4–9]. Our results suggest that NAC induced
perturbations of the mitochondrial redox potential, triggering this
mitohormesis phenomenon.
The transcriptional control of mitochondrial biogenesis depends on
many factors, and the members of the PGC-1 family (PGC-1α; PGC-1β,
and PRC) are considered to be key regulators of this process [37–39].
The conventional wisdom attributes oxidative stress response to PGC-
1α, however the regulation and function of PGC-1β is still unclear in
the literature. Both are enriched in mitochondria-rich tissues, but PGC-
1β is thought to preferentially induce genes involved in the removal
of reactive oxygen species and is supposed to play a role in constitutive
mitochondrial biogenesis [40]. However, only PGC-1α is thought to re-
spond to metabolic challenges. Indeed, we found a rapid transcriptional
activation leading to the increased expression of several genes implicat-
ed in mitochondrial biogenesis pathways, including PGC-1β, the NRF
family, and TFAm [12,37–39,41–43].We observed however a signiﬁcant
increase in the expression of the PGC-1α protein at 7 days despite what
we observed at the mRNA level. That is why we can suggest that the
adaptive response observed in our study could be driven through
PGC-1α, but we cannot exclude that this adaptive response does only
affect PGC-1α protein levels and not PGC-1β. Then, the mRNA results
suggest that the establishment of the mitohormesis phenotype at
7 days needs both PGC-1α and β induction, with PGC-1β expression
being required earlier in the mitohormesis time course than PGC-1α.
Mitochondrial adaptations could be considered as a sequential program,
requiring 6 to 10 days to obtain an effective mitochondrial biogenesis
[44]. We studied the effects of one week of NAC treatment to assess
the phenotypic consequences of this activation of biogenesis. In our
study, we clearly showed that the activation of mitochondrial biogene-
sis led to an increase in cellular levels of mitochondrial content as well
as cellular antioxidant capacities. These phenotypic changes were dem-
onstratedwith several techniques. First, we showed an augmentation of
the relative mRNA expression of mitochondrial proteins, such as citrate
synthase, as well as the simultaneous expression of nuclear and mito-
chondrial genomes, with an increase in the relative mRNA expression
of subunits of cytochrome c oxidase (complex IV), COX1 (encoded
by the mitochondrial genome) and COX4 (encoded by the nuclear
genome). This simultaneous expression of both genomes could be
explained by TFAm overexpression. These observations were corrobo-
rated by Western blot results showing an effective upregulation at the
protein level of mitochondrial biogenesis pathways, as well as by an in-
crease in themtDNA copy number. At the functional level, we observed
an augmentation of the mitochondrial maximal oxidative capacities
(Vmax). Interestingly, the antioxidant enzymatic systems were clearly
enhanced, allowing a decrease in the cellular ROS content measured
by electron spin resonance. These results are consistent with numerous
ﬁndings indicating that ROSmay evoke cellular signaling that promotesmetabolic health and longevity. Indeed, ROS serve as essential signaling
molecules delivering messages from the mitochondria to other cellular
compartments in response to physiological or pathophysiological
changes [6,35,45–49]. Classically, N-acetylcysteine (NAC) is considered
to be an antioxidant molecule because it is the most immediate precur-
sor of glutathione (GSH), which is the main mechanism of detoxiﬁca-
tion of free radicals and ionized metabolites [16,17], especially in
mitochondria. Our ﬁndings are quite novel in demonstrating that NAC
has powerful mitochondrial and antioxidant effects, not only via its
properties as a glutathione precursor (increase in GSH content) but
also by enhancing the levels of mitochondrial content and antioxidant
enzymes by triggering mitohormesis. According to Calabrese et al.,
this phenomenon could be deﬁned as chemical conditioning hormesis
[50]. Moreover, our results could partially explain the divergent and
sometimes disappointing effects encountered with chronic NAC treat-
ment and antioxidant supplementation [51–57]. Indeed, reductive
stress could lead to an increase in mitochondrial oxidation due to
these so-called antioxidants and have dramatic effects on redox path-
ways and on cell survival.
4.3. Mitochondrial hormesis protected cells from pro-apoptotic effects of
statins
Statins are the most prescribed and most efﬁcient medication used
to lower plasma cholesterol levels [58] and are considered relatively
clinically safe. However, these molecules show numerous adverse ef-
fects ranging frommyalgia to rhabdomyolysis. These deleterious effects
have been shown to be linked to oxidative stress in glycolytic skeletal
muscles, whereas cardiac oxidative muscle, which has a higher mito-
chondrial content as well as higher antioxidant properties, was pre-
served [4]. An increase of mitochondrial content in L6 myoblasts has
been shown to protect against both caspase-dependent and caspase-
independent apoptosis [59]. Therefore, statin-induced mitochondrial
ROS overproduction may lead to the triggering of apoptotic pathways
and lead to the appearance of statin-induced myopathy. We observed
that three days of pretreatmentwithNAC 1mMwas not sufﬁcient to in-
duce mitochondrial hormesis. At this time point, NAC pretreated cells
seems to be weakened by the induced mitochondrial oxidation, and so
more affected by a subsequent mitochondrial stress with statins. Thus,
in our conditions we observed that the switch to an effective hormetic
protective phenotype occurs between an incubation time superior to
3 days, and an incubation time inferior or equal to one week. Indeed,
seven days of NAC exposure seem to be necessary in order to increase
mitochondrial content via mitohormesis. This phenomenon was able
to protect cells against statin-induced toxic effects. Moreover, the pro-
tection provided by NAC does not occur through its known antioxidant
action, but seems more likely due to the triggering of adaptive path-
ways. Even though NAC pretreatment does not remove totally the dele-
terious of statins, it enabled to maintain a mitochondrial functionality
comparable to the CTL group. Statins are known to alter mitochondrial
function via a direct inhibitorymechanism of themitochondrial respira-
tory chain, thus decreasing ATP content and increasing ROS production
[4]. The improvement of themitochondrial function observed after NAC
pretreatment protected cells against a subsequent mitochondrial stress
with statins by diminishing cell death and the triggering of apoptotic
pathways. Mitochondrial phenotype appears to be a key factor in the
triggering of statins' myopathy, and switching muscle ﬁber type from
glycolytic to oxidative by increasingmitochondrial content could repre-
sent a potential therapy to protect muscles from statins' myopathy.
5. Conclusions
We showed that the antioxidant N-acetylcysteine provoked a cellu-
lar reductive stress, which led to mitochondrial malfunction. The
resulting mitochondrial oxidation leads to the triggering of mitochon-
drial biogenesis pathways via a mitohormesis mechanism, leading to
1584 F. Singh et al. / Biochimica et Biophysica Acta 1853 (2015) 1574–1585an increase of mitochondrial content combined with an improvement
of antioxidant capacities in L6 myoblasts. This process allowed a de-
crease in oxidative stress and provided protection against apoptosis,
as previously described in another model [59]. This improved cell sur-
vival after atorvastatin treatment. To our knowledge, this is the ﬁrst
study showing that reductive stress could trigger the mitochondrial
hormesis phenomenon.
Moreover, our ﬁndings underscore the importance of considering
the dynamic events related to both oxidative and reductive stress with-
in cells. Thus, molecules chemically considered as antioxidants might
have dramatic effects on oxido-reductive signals and redox-dependant
pathways. Mitochondrial content and cellular antioxidant power seem
to be determining factors in the appearance of statin-induced myopa-
thy; thus, the activation of this mitohormesis phenomenon represents
a potential new therapeutic solution to reduce the toxicity of com-
pounds affecting mitochondrial function. For example, ﬁnding a mole-
cule able to increase mitochondrial content in skeletal muscle in vivo
could provide a protection against statin-induced myopathy.
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